Stem Cell Intel Newsletter

Each quarter, Stem Cell Intel will provide you with the latest product news, a column from one of our experts, upcoming industry events, and easy access to technical tools such as publications, protocols, FAQs, and more. To receive Stem Cell Intel, please click the subscribe button below.

Subscribe to Stem Cell Intel


Our top 10 stories of 2014

Over the course of the last year, Stem Cell Intel has provided you with the latest in stem cell research. Let’s recap the highlights from 2014!


Revamped next-gen conferencing with the 2nd annual 24 Hours of Stem Cells virtual event: 1,000 Researchers. Five Continents. One Day.

Got to the heart of stem cells with the PSC Cardiomyocyte Differentiation Kit—efficient differentiation from hPSCs to contracting cardiomyocytes in as few as 8 days.

Provided an enchanting experience at the International Society for Stem Cell Research (ISSCR)—relive the magic!

Launched the PSC Immunocytochemistry Kit—the only commercial kit offering superior imaging for pluripotent stem cells in one box.

Reported on disease modeling using stem cells—in a series of white papers, we described our case studies for creating Parkinson’s disease cell models using our tools.

Launched the PSC Cryopreservation Kit—optimized for maximum post-thaw viability and recovery of cryopreserved pluripotent and human embryonic stem cells.

Unveiled Rupa’s Corner—an outstanding column from one of our very own stem cell experts, Rupa Shevde.

Unveiled Lipofectamine® 3000 Transfection Reagent—unleashes the power of stem cells by providing a highly efficient nucleic acid delivery alternative to electroporation.

Updated our reprogramming tools and resources—frequently asked questions, protocols, and scientific posters available for all your reprogramming needs.

Introduced the Human NSC Immunocytochemistry Kit—confidently assess expression of Sox1, Sox2, nestin, and Pax6.


Rupa's corner

 

Significant advances in stem cell research

In the past two decades, stem cell science has made significant advancements in both basic research and clinical fields. There have been noteworthy discoveries in basic research. Elsevier recently partnered with EuroStemCell and Kyoto University’s Institute for Integrated Cell-Material Sciences (iCeMS) to study publication trends in stem cell research. The number of publications has grown from 4,402 in 1996 to 21,193 publications in 2012, showing a compound annual growth rate of 7.0% compared to the world average growth rate of 2.9% across all disciplines. While the US leads with the highest number of publications and China is second, many other countries such as Singapore and Korea have also seen significant increases. Interestingly, almost half of all stem cell publications are focused on either regenerative medicine or drug development, and this is predominantly seen in iPS cell research.

The most notable recent advances in the clinical arena include two reports:

  1. Japanese scientists and clinicians were successful in transplanting a large sheet (1.3 x 3.0 mm) of autologous iPS-derived retinal pigment epithelial (RPE) cells into a 70-year-old patient, who continues to do well after the transplant. This is the world’s first clinical trial using iPS cells.
  2. The Lancet journal reported the first-ever clinical trial by Advanced Cell Technologies (ACT) using hES cell–derived RPEs, where 18 patients displayed safety and promising efficacy results in treatment of macular degeneration.

These trends are testament to the fact that the stem cell field is advancing at a rapid pace with extraordinarily positive results, making it okay to feel optimistic!

Reference: EuroStemCell , iCeMS, Elsevier (2013) “Stem Cell Research: Trends and Perspectives on the Evolving International Landscape”.

Featured events

Stem Cell Characterization: Challenges and Strategies

Thermo Fisher Scientific recently sponsored a webinar hosted by The Scientist titled “Stem Cell Characterization: Challenges and Strategies”. Topics from the on-demand webinar included:

  • Basic concepts underlying stem cell identification and current industry standards
  • Approaches and considerations for stem cell isolation and characterization
  • Strategies for incorporating appropriate tools into your workflow

The panel of featured speakers included Dr. Tenneille Ludwig, Director of the WiCell Stem Cell Bank in Madison, Wisconsin, and Dr. April Pyle, Associate Professor of Microbiology, Immunology, and Molecular Genetics at the University of California, Los Angeles.

Register to see the on-demand webinar now


Technical highlights

Join researchers worldwide switching to Geltrex matrix

  Feeder-free media condition 1 Feeder-free media condition 2
Colony morphology Comparable Comparable
Cell attachment after 72 hours Comparable Geltrex matrix is superior
SSEA4 expression Comparable Comparable
Karyotype Normal ND

In a recent side-by-side comparison with the leading basement membrane extract, Geltrex hESC SFM achieved the results shown above. Because the recommended dilution factor differs by a factor of 3 from the leading extract, you could be saving 50% or more on cost per cm2 basis when using Geltrex matrix.

Start saving money on your matrix today

New Data: PSC Cardiomyocyte Differentiation Kit

Shown above is the response of spontaneous beat rate on cardiomyocytes differentiated using the PSC Cardiomyocyte Differentiation Kit, measured using the Multi Electrode Array. These data show that cardiomyocytes generated using this new kit can be used to model the change in spontaneous beat rate of the heart caused by drugs that alter the activity of ion channels.  

Learn more about the PSC Cardiomyocyte Differentiation Kit